Immune response, phenotyping and molecular graft surveillance in kidney transplant recipients following severe acute respiratory syndrome coronavirus 2 vaccination
© 2023 Wiley Periodicals LLC..
BACKGROUND: Understanding immunogenicity and alloimmune risk following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in kidney transplant recipients is imperative to understanding the correlates of protection and to inform clinical guidelines.
METHODS: We studied 50 kidney transplant recipients following SARS-CoV-2 vaccination and quantified their anti-spike protein antibody, donor-derived cell-free DNA (dd-cfDNA), gene expression profiling (GEP), and alloantibody formation.
RESULTS: Participants were stratified using nucleocapsid testing as either SARS-CoV-2-naïve or experienced prior to vaccination. One of 34 (3%) SARS-CoV-2 naïve participants developed anti-spike protein antibodies. In contrast, the odds ratio for the association of a prior history of SARS-CoV-2 infection with vaccine response was 18.3 (95% confidence interval 3.2, 105.0, p < 0.01). Pre- and post-vaccination levels did not change for median dd-cfDNA (0.23% vs. 0.21% respectively, p = 0.13), GEP scores (9.85 vs. 10.4 respectively, p = 0.45), calculated panel reactive antibody, de-novo donor specific antibody status, or estimated glomerular filtration rate.
CONCLUSIONS: SARS-CoV-2 vaccines do not appear to trigger alloimmunity in kidney transplant recipients. The degree of vaccine immunogenicity was associated most strongly with a prior history of SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 25(2023), 6 vom: 01. Dez., Seite e14122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ali, Nicole M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 26.12.2023 Date Revised 26.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.14122 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362045356 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362045356 | ||
| 003 | DE-627 | ||
| 005 | 20231227141255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.14122 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1239.xml |
| 035 | |a (DE-627)NLM362045356 | ||
| 035 | |a (NLM)37707287 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ali, Nicole M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune response, phenotyping and molecular graft surveillance in kidney transplant recipients following severe acute respiratory syndrome coronavirus 2 vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2023 | ||
| 500 | |a Date Revised 26.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Understanding immunogenicity and alloimmune risk following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in kidney transplant recipients is imperative to understanding the correlates of protection and to inform clinical guidelines | ||
| 520 | |a METHODS: We studied 50 kidney transplant recipients following SARS-CoV-2 vaccination and quantified their anti-spike protein antibody, donor-derived cell-free DNA (dd-cfDNA), gene expression profiling (GEP), and alloantibody formation | ||
| 520 | |a RESULTS: Participants were stratified using nucleocapsid testing as either SARS-CoV-2-naïve or experienced prior to vaccination. One of 34 (3%) SARS-CoV-2 naïve participants developed anti-spike protein antibodies. In contrast, the odds ratio for the association of a prior history of SARS-CoV-2 infection with vaccine response was 18.3 (95% confidence interval 3.2, 105.0, p < 0.01). Pre- and post-vaccination levels did not change for median dd-cfDNA (0.23% vs. 0.21% respectively, p = 0.13), GEP scores (9.85 vs. 10.4 respectively, p = 0.45), calculated panel reactive antibody, de-novo donor specific antibody status, or estimated glomerular filtration rate | ||
| 520 | |a CONCLUSIONS: SARS-CoV-2 vaccines do not appear to trigger alloimmunity in kidney transplant recipients. The degree of vaccine immunogenicity was associated most strongly with a prior history of SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 vaccination | |
| 650 | 4 | |a graft biomarker | |
| 650 | 4 | |a immunogenicity | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Herati, Ramin S |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Sapna A |e verfasserin |4 aut | |
| 700 | 1 | |a Leonard, Jeanette |e verfasserin |4 aut | |
| 700 | 1 | |a Miles, Jake |e verfasserin |4 aut | |
| 700 | 1 | |a Lonze, Bonnie E |e verfasserin |4 aut | |
| 700 | 1 | |a DiMaggio, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Tatapudi, Vasishta S |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Zoe A |e verfasserin |4 aut | |
| 700 | 1 | |a Alnazari, Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Neumann, Henry J |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Cartiera, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Weldon, Elaina |e verfasserin |4 aut | |
| 700 | 1 | |a Michael, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Hickson, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Whiteson, Harris |e verfasserin |4 aut | |
| 700 | 1 | |a Khalil, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Stern, Jeffrey M |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Joseph R |e verfasserin |4 aut | |
| 700 | 1 | |a Tuen, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Gray-Gaillard, Sophie L |e verfasserin |4 aut | |
| 700 | 1 | |a Solis, Sabrina M |e verfasserin |4 aut | |
| 700 | 1 | |a Samanovic, Marie I |e verfasserin |4 aut | |
| 700 | 1 | |a Mulligan, Mark J |e verfasserin |4 aut | |
| 700 | 1 | |a Montgomery, Robert A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 25(2023), 6 vom: 01. Dez., Seite e14122 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:6 |g day:01 |g month:12 |g pages:e14122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.14122 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 6 |b 01 |c 12 |h e14122 | ||